Effect of N-Acetyl-cysteine On platelet Engraftment post Auto-HSCT

Effect of N Acetyl cysteine on platelet engraftment post autologous bone marrow transplantation in comparison to control group

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211123053165N1

Enrollment

Registered

2021-12-22

Start date

2021-12-22

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: MULTIPLE MYELOMA. Condition 2: LYMPHOMA. Condition 3: Auto-Hsct. Multiple myeloma Hodgkin lymphoma

Interventions

Intervention 1: Intervention group: patients with Multiple Myeloma or Lymphoma that their diseases are in complete remission and are candidate of Auto-HSCT, will be received N-Acetyl cysteine tablets,

Eligibility

Sex/Gender

All

Age

16 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with Multiple Myeloma who are eligible for Auto-HSCT Patients with Lymphoma who are eligible for Auto-HSCT

Exclusion criteria

Exclusion criteria: History Of Allergic Reaction to N-Acetyl cysteine or its ingredients History of Bronchial Asthma

Design outcomes

Primary

Measure	Time frame
Median Platelet number post auto-Hsct. Timepoint: During admition daily then weekly for at least 3 weeks. Method of measurement: complete blood count test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRasoul Ghasemian

Esfahan University of Medical Sciences

rasoolqasemian@yahoo.com+98 31 3226 1922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026